Volume 6, Number 8
Monday, February 27, 2006



In this issue: (click heading to view article)
Surgery-Related Factors and Postkeratoplasty CNV
Retinal Vessel Diameters and Risk of Impaired Fasting Glucose or Diabetes
Early ARM After Cataract Surgery
Briefly











Surgery-Related Factors and Postkeratoplasty CNV

This Vietnamese study aimed to identify the speed of corneal neovascularization (CNV) after penetrating keratoplasty (PK) and to evaluate the influence of surgery-related factors on postkeratoplasty CNV in keratoconus patients.

The prospective, longitudinal, observational case series study included 66 consecutive primary PKs performed for keratoconus by four experienced surgeons between January 1, 2000, and December 31, 2002, at one department. Standardized corneal photographs taken preoperatively, and investigators evaluated them at six weeks, three months, six months, 12 months, 18 months and 24 months postoperatively. They measured limbus suture distance (LSD), limbus graft distance (LGD), inner suture angle (ISA) and maximal extension of CNVs in digitized pictures with 100-fold magnification at each of the 16 suture turning points at every timepoint.

Forty-four out of 66 corneal grafts (67 percent) developed some degree of CNV after PK, most commonly from around the 12 o"clock position. The mean speed of CNV growth was 114 microns/month, with the fastest growth occurring during the first six weeks after PK. Results showed an inverse correlation between CNV and LSD, LGD and ISA. Ninety percent of all CNVs developed with LSD less than 406 microns and with LGD less than 1000 microns.

The authors identified small LSD, small LGD and narrow stitching with small ISA as potentially modifiable surgical risk factors for CNV after PK. Because the speed of CNV outgrowth was most pronounced in the first weeks after PK, the authors emphasize the importance of making early postoperative controls for CNV growth and initiation of antiangiogenic treatment.

SOURCE: Lam VM, Nguyen NX, Martus P, et al. Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. Am J Ophthalmol 2006;141(2):260-6.
Table of Contents






Retinal Vessel Diameters and Risk of Impaired Fasting Glucose or Diabetes

Researchers at the Netherlands Ophthalmic Research Institute investigated associations between baseline vessel diameters and incident impaired fasting glucose or diabetes in a population-based cohort (aged 55 years or older) to determine whether the association between a smaller retinal arteriolar-to-venular ratio (AVR) and incident diabetes is due to arteriolar narrowing, venular dilatation or both.

Baseline retinal vessel diameters (1990 to 1993) were measured on digitized images of 2,309 subjects with a normal glucose tolerance test (postload glucose less than 7.8 mmol/l). At follow-up (1997 to 1999), impaired fasting glucose was defined as 6.1 to 7.0 mmol/l and diabetes as 7.0 mmol/l or greater and/or antidiabetic medication use. Odds ratios (ORs) per SD increase in venular diameters were 1.13 (95 percent CI, 1.00 to 1.29) for impaired fasting glucose and 1.09 (0.90 to 1.33) for diabetes. ORs per SD decrease in arteriolar diameters were 1.12 (0.98 to 1.27) and 1.08 (0.89 to 1.31) and per SD decrease in AVR were 1.29 (1.13 to 1.46) and 1.19 (0.98 to 1.45).

After adjustment for cardiovascular risk factors, the associations were unaltered for venules and disappeared for arterioles. After stratification on age, associations between venular dilatation and impaired fasting glucose (1.23 [1.02 to 1.47]) or diabetes (1.18 [0.89 to 1.56]) were mainly present in participants aged 70 years or younger. The authors of the study concluded that the risk of impaired fasting glucose and diabetes with AVR was explained by venular dilatation rather than arteriolar narrowing, and they believe this warrants greater focus on the causes of this dilatation.

SOURCE: Ikram MK, Janssen JA, Roos AM, et al. Retinal vessel diameters and risk of impaired fasting glucose or diabetes: the Rotterdam Study. Diabetes 2006;55(2):506-10.
Table of Contents






Early ARM After Cataract Surgery

Australia’s Centre for Vision Research conducted a study to assess age-related maculopathy (ARM) in eyes of patients who had undergone cataract surgery at least a year earlier.

Consecutive patients aged 60 years or older who had undergone cataract surgery at Westmead Hospital, Sydney, Australia, during 2001 to 2003 were examined in 2004. Investigators conducted interviews using standardized questionnaires and stereo retinal photography. They graded the retinal photographs using the Wisconsin ARM grading system, then compared the proportions with ARM between surgical and nonsurgical eyes, and between this surgical cohort and the Blue Mountains Eye Study (BMES) population.

Of the 622 eligible patients, 454 (73 percent) were re-examined, with a mean follow-period of 2.8 years. Surgical eyes had a higher proportion of early ARM compared to nonsurgical eyes (15.2 vs. 10.3 percent) and to the early ARM prevalence found in BMES participants of similar age (14.5 vs. 6.9 percent), which persisted after age standardization to the BMES population (9.7 vs. 6.9 percent).

The authors found an increased prevalence of early ARM in surgical eyes of patients one to three years after cataract surgery. They believe that additional study is required to determine whether this increased early ARM prevalence leads to an increased prevalence of late ARM in the long term.

SOURCE: Pham TQ, Cugati S, Rochtchina E, et al. Early age-related maculopathy in eyes after cataract surgery. Eye 2006; Jan 27 [Epub ahead of print].
Table of Contents





BRIEFLY
  • HEIDELBERG RECEIVES FDA CLEARANCE FOR ANTERIOR SEGMENT OCT. Heidelberg Engineering GmbH has received FDA clearance for its SL-OCT optical coherence tomography (OCT) device used for cross-sectional anterior segment imaging. The SL-OCT was first introduced in Europe and received CE mark certification in 2003. The device is the first commercial application of OCT for anterior segment imaging; its mounting on a slit lamp also offers space savings and cost advantages. It offers chamber angle, pachymetry, flap thickness, corneal curvature and comprehensive biometric measurements, as well as pre- and post-surgical comparisons. Based on this OCT technology, Heidelberg is also marketing two additional products in Europe: OCPglobal, a stand-alone pachymeter, and OCPonline, an online pachymeter for integration into refractive laser systems. The online pachymeter enables refractive lasers to obtain noncontact corneal thickness measurements immediately before, during and after surgery. For more information, go to www.heidelbergengineering.com.
  • OPHTHONIX RECEIVES ADDITIONAL PATENT FOR WAVEFRONT-GUIDED LENS. Ophthonix has received an eighth patent relating to its iZon Wavefront-Guided Lens. The newest patent supports aspects of the manufacturing process that allows Ophthonix to produce customized and optically exact lenses. The patented Ophthonix process consists of controlled amounts of polymers micro-jetted onto optical material to form polymer pixels; these pixels provide vision needs specific to each patient, and supply refractive properties that correct for relatively complicated or higher-order aberrations, including coma, trefoil, spherical aberration, tetrafoil, distortion and astigmatism. The company says that iZon lenses will be available in major markets across the United States by the end of 2006. For more information, go to www.ophthonix.com.
  • PRELIMINARY RESULTS ANNOUNCED FOR OVERSEAS CLINICAL TRIALS OF TWO GLAUCOMA DRUG CANDIDATES. Santen Pharmaceutical Co., Ltd., has announced preliminary results for overseas clinical trials of two drug candidates for lowering intraocular pressure (IOP) in glaucoma and ocular hypertension: an angiotensin II receptor antagonist, DE-092 (INN: Olmesartan), and a prostaglandin derivative, DE-085 (INN: Tafluprost). The company conducted an early Phase II clinical study of DE-092 in the United States; data analysis indicated some IOP reduction for DE-092, but efficacy was insufficient and no clear dose-response relationship was observed among the DE-092 concentrations. Santen is considering conducting another dose-response study and re-positioning of DE-092 in the United States and Europe after the Japanese Phase II results are available. Santen is also conducting several DE-085 comparison studies in the United States and Europe. The company has conducted a European Phase III trial designed to confirm DE-085"s non-inferiority to latanoprost ophthalmic solution 0.005% (latanoprost). Results demonstrated a strong IOP-lowering effect, but DE-085 did not demonstrate non-inferiority to latanoprost. Santen will review the development plan for DE-085 in the U.S. and Europe after completing a comprehensive statistical analysis of data from another comparison study versus timolol maleate ophthalmic solution 0.5% (timolol), currently ongoing in the United States and Europe. In Japan, Santen has conducted several Phase III studies, including a comparison study with latanoprost that demonstrated DE-085"s non-inferiority to latanoprost.


Table of Contents



 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
The Check Yearly. See Clearly.(SM) marketing campaign is opening consumers' eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.